PMA device
ReActiv8 Implantable Neurostimulation System
Mainstay Medical Limited · Stimulator, Neuromuscular, Lower Back Muscles, Totally Implanted For Pain Relief (QLK, Class III) · First FDA decision Jun 16, 2020, newest Jun 20, 2025Chronic painLow back pain
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
5
Naming "ReActiv8"
MAUDE reports
470
Brand "ReActiv8", since 2015
PubMed studies
14
Mentioning "ReActiv8"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ReActiv8 Implantable Neurostimulation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- ReActiv8 Implantable Neurostimulation SystemPMA supplement
P190021-S009 · Decided Jun 20, 2025 · 87 days after receipt · Normal 180 Day Track
Device type: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief (QLK) · Neurology & Neurosurgery
- ReActiv8 Implantable Neurostimulation SystemPMA supplement
P190021-S005 · Decided Aug 24, 2023 · 140 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief (QLK) · Neurology & Neurosurgery
- ReActiv8 Implantable Neurostimulation SystemPMA supplement
P190021-S001 · Decided Jan 8, 2024 · 543 days after receipt · Normal 180 Day Track
Device type: Stimulator, neuromuscular, lower back muscles, totally implanted for pain relief (QLK) · Neurology & Neurosurgery
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "ReActiv8", any status and sponsor, newest update first.
- Multifidus PET Scan StudyActive, not recruiting
Barts & The London NHS TrustAcademic, hospital or other
NCT04327817 · 20 participants · Start Aug 19, 2021 · Primary completion Mar 17, 2027
Device: Multifidus stimulator · For: Low Back Pain
Sites: London, United Kingdom
- ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized EvaluationPivotal-lookingCompleted
Mainstay MedicalNot on our public-company list
NCT04803214 · 203 participants · Start Jul 14, 2021 · Primary completion Sep 4, 2024
Device: ReActiv8 · For: Chronic Low-back Pain
Sites: Phoenix, Arizona; Little Rock, Arkansas; Newport Beach, California · 28 sites in all
- ReActiv8 Implantable Neurostimulation System for Chronic Low Back PainPivotal-lookingCompleted
Mainstay MedicalNot on our public-company list
NCT02577354 · 204 participants · Start Aug 2016 · Primary completion Nov 2018
Device: ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation); ReActiv8 Implantable Stimulation System (Low Stimulation) · For: Chronic Low Back Pain
Sites: La Jolla, California; Santa Monica, California; Aurora, Colorado · 26 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ReActiv8", and for the whole product code for context.
This brand
470 reports: 212 malfunction, 258 injury, 0 death
Whole product code QLK
479 reports: 217 malfunction, 262 injury, 0 death
Newest reports for this brand
- ReActiv8Malfunction
3021520203-2026-00139 · Received Oct 28, 2026 · Event dated Sep 3, 2025
Device type: Stimulator, Neuromuscular, Lower Back Muscles, Totally Implanted For Pain Relief (QLK)
Device problem as coded: Failure to Conduct
Patient problem as coded: Failure of Implant
- ReActiv8Malfunction
3021520203-2026-00138 · Received Oct 28, 2026 · Event dated Aug 2, 2024
Device type: Stimulator, Neuromuscular, Lower Back Muscles, Totally Implanted For Pain Relief (QLK)
Device problem as coded: Failure to Conduct
Patient problem as coded: Failure of Implant
- ReActiv8Injury
3021520203-2026-00135 · Received Oct 23, 2026 · Event dated Sep 22, 2026
Device type: Stimulator, Neuromuscular, Lower Back Muscles, Totally Implanted For Pain Relief (QLK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Implant Pain
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ReActiv8"[tiab]. The summary above synthesizes these.
- Application of restorative neurostimulation for chronic mechanical low back pain in an older population with 2-year follow up.
Ardeshiri A, Amann M, Thomson S, et al. · Reg Anesth Pain Med · 2025Research Support, Non-U.S. Gov't
- Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact.
Shaffrey C, Gilligan C · Neurosurgery · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- ReActiv8 Stimulation Therapy vs. Optimal Medical Management: A Randomized Controlled Trial for the Treatment of Intractable Mechanical Chronic Low Back Pain (RESTORE Trial Protocol).
Gilligan C, Burnside D, Grant L, et al. · Pain Ther · 2023
- Five-Year Longitudinal Follow-Up of Restorative Neurostimulation Shows Durability of Effectiveness in Patients With Refractory Chronic Low Back Pain Associated With Multifidus Muscle Dysfunction.
Gilligan C, Volschenk W, Russo M, et al. · Neuromodulation · 2024Randomized Controlled Trial
- Durability of the Therapeutic Effect of Restorative Neurostimulation for Refractory Chronic Low Back Pain.
Mitchell B, Deckers K, De Smedt K, et al. · Neuromodulation · 2021
- Three-Year Durability of Restorative Neurostimulation Effectiveness in Patients With Chronic Low Back Pain and Multifidus Muscle Dysfunction.
Gilligan C, Volschenk W, Russo M, et al. · Neuromodulation · 2023Observational Study, Randomized Controlled Trial
- Peripheral Nerve Stimulation for Low Back Pain: A Review of the Recent Literature.
Xiao JT, Rana N, Rana M · Curr Pain Headache Rep · 2025Review
- Comprehensive Evidence-Based Guidelines for Implantable Peripheral Nerve Stimulation (PNS) in the Management of Chronic Pain: From the American Society Of Interventional Pain Physicians (ASIPP).
Manchikanti L, Sanapati MR, Soin A, et al. · Pain Physician · 2024
- New Therapy for Refractory Chronic Mechanical Low Back Pain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial.
Deckers K, De Smedt K, Mitchell B, et al. · Neuromodulation · 2018Multicenter Study
- Long-Term Outcomes of Restorative Neurostimulation in Patients With Refractory Chronic Low Back Pain Secondary to Multifidus Dysfunction: Two-Year Results of the ReActiv8-B Pivotal Trial.
Gilligan C, Volschenk W, Russo M, et al. · Neuromodulation · 2023Randomized Controlled Trial
- ISASS Recommendations and Coverage Criteria for Restorative Neurostimulation for Multifidus Dysfunction, Lumbar Region: Coverage Indications, Limitations, and/or Medical Necessity-An ISASS 2025 Guideline Update.
Lorio MP, Lewandrowski KU, Lavelle W, et al. · Int J Spine Surg · 2025
- Complications of ReActiv8 for chronic low back pain: an analysis of the FDA MAUDE database.
Conic RRZ, Kivanc T, Fischer A, et al. · Pain Manag · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.